newsfilter
← Latest News
GlobeNewswire·

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 - - Solid has scheduled a Type C meeting with the FDA